Recothrom

Drug Overview

In the fast-paced and critical field of hematology and surgical care, controlling blood loss is essential for patient survival and recovery. Recothrom is an advanced medication classified as a Topical Hemostatic (Recombinant Thrombin). It is a highly specialized BIOLOGIC designed to quickly stop minor bleeding during surgery when standard techniques, like stitching or cauterizing, are not enough.

Because it is a recombinant product, Recothrom is produced in a laboratory using advanced cell culture technology rather than being extracted from human or animal blood. This eliminates the risk of transmitting blood-borne diseases and greatly reduces the chance of the patient developing harmful antibodies, which was a common problem with older, animal-derived thrombin products.

• Generic Name: thrombin alfa (recombinant)
• US Brand Names: Recothrom
• Route of Administration: Topical application (applied directly to the tissue)
• FDA Approval Status: FDA-approved as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible, and control of bleeding by standard surgical techniques is ineffective or impractical.
  
  Learn essential facts about Recothrom. Discover its key medical uses, vital health benefits, potential side effects, and exact patient dosage.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Recothrom works, it helps to look at the body’s natural blood-clotting process, known as the coagulation cascade. When a blood vessel is cut, the body triggers a chain reaction of proteins (clotting factors) to stop the bleeding. The final and most important step of this cascade involves an enzyme called thrombin.

Recothrom acts as a TARGETED THERAPY that delivers this crucial enzyme directly to the wound. At the molecular and hematological level, the mechanism of action is direct and immediate:

1. Fibrinogen Conversion: Once applied to the bleeding tissue, the recombinant thrombin mixes with the patient’s own blood. It immediately targets a protein in the blood called fibrinogen.
2. Fibrin Formation: Thrombin acts like molecular scissors, cutting fibrinogen into sticky, thread-like strands called fibrin.
3. Clot Stabilization: These fibrin strands weave together to form a sturdy, net-like web (a clot) that traps red blood cells and platelets, effectively plugging the leak.

By acting at the very end of the coagulation cascade, Recothrom bypasses the need for vitamin K-dependent factors. This direct action provides rapid hemorrhage risk reduction, securing the bleeding site within minutes.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Recothrom in the hematology and surgical setting is surgical bleeding control. It is used as an adjunct (add-on) therapy during surgery to stop mild to moderate oozing from small blood vessels. Surgeons rely on this BIOLOGIC when standard methods—such as applying pressure, tying off vessels (ligation), or using heat (electrocautery)—cannot be used or are not working well enough.

Other Approved & Off-Label Uses

While specifically indicated for general surgical bleeding, it is utilized across multiple surgical specialties. Uses include:

• Use in combination with an absorbable gelatin sponge to create a physical patch over the bleeding site.
• Spinal and neurosurgery to control oozing near delicate nerve tissues where heat sealing is dangerous.
• Liver and kidney resections to manage bleeding from large, porous tissue surfaces.
• Vascular surgery to seal microscopic leaks around surgical blood vessel grafts (off-label when used with specific non-approved carrier matrices).
• Burn debridement to control widespread capillary bleeding over large surface areas.

Dosage and Administration Protocols

Recothrom is strictly for topical use on the surface of tissues. It must never be injected. The dosage depends entirely on the size of the bleeding area and the severity of the bleeding.

Important Adjustments:

• Maximum Infusion Rates: Not applicable. This medication is not infused into the bloodstream. It is applied topically using a spray syringe or poured onto a gelatin sponge.
• Renal/Hepatic Insufficiency: No dose adjustments are required for patients with kidney or liver disease because the medication acts locally on the tissue and is not processed systemically.
• Preparation: The sterile powder must be reconstituted (mixed) with the provided sterile saline immediately before use.

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) continues to validate the safety and efficacy of recombinant thrombin over traditional bovine (cow-derived) thrombin. In pivotal Phase 3 clinical trials involving various surgical procedures, Recothrom successfully achieved hemostasis (stopped bleeding) within 10 minutes in over 95 percent of patients.

Importantly, numerical data highlights its superior immune safety. Historically, up to 20 percent of patients exposed to bovine thrombin developed antibodies that could mistakenly attack their own human clotting factors, leading to severe bleeding disorders. Research confirms that the incidence of developing these dangerous antibodies with Recothrom is practically zero, cementing this BIOLOGIC as a safer alternative for patients requiring surgical bleeding control.

Safety Profile and Side Effects

Black Box Warning

There is no boxed warning for Recothrom. However, there is a severe contraindication: Do not inject directly into the circulatory system. If this topical medication is accidentally injected into a blood vessel, it can cause immediate, widespread, and fatal blood clots.

Common side effects (>10%)

Because this medication is used during surgery, most side effects are related to the surgical procedure itself rather than the drug. Common events include:

• Nausea and vomiting
• Incision site pain
• Fever
• Mild anemia

Serious adverse events

• VTE/thrombosis risk: If the product accidentally enters a large, open blood vessel during application, it can cause severe deep vein thrombosis, pulmonary embolism, or stroke.
• Hypersensitivity: Severe allergic reactions (anaphylaxis) are rare but possible, particularly in patients with a known allergy to hamster proteins (as the drug is manufactured using Chinese Hamster Ovary cells).

Management Strategies

To prevent serious complications, the surgical team must ensure the bleeding site is relatively dry (by blotting, not wiping) before application to prevent the thrombin from washing into systemic circulation. If a severe allergic reaction occurs during the procedure, the medical team will provide immediate cardiovascular support and administer medications like epinephrine.

Research Areas

In the advancing field of surgical hematology, ongoing research is exploring new, innovative ways to deliver this TARGETED THERAPY. Active clinical trials are investigating combining recombinant thrombin with novel, biodegradable synthetic patches that do not rely on animal-derived gelatin. Additionally, researchers are testing specialized endoscopic spray catheters that allow surgeons to apply Recothrom deep into the body during minimally invasive and robotic surgeries, providing faster bleeding control with smaller incisions.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

Since Recothrom is used during surgery, standard pre-operative tests are required:

• Complete Blood Count (CBC): To establish baseline red blood cell and platelet counts.
• Coagulation Studies: PT/INR and aPTT to identify any underlying bleeding disorders that might complicate surgery.
• Organ Function: Standard metabolic panels to assess overall health before anesthesia.

Precautions during treatment

• Strict Application Protocol: The surgical team must use strict vigilance to ensure the product is only applied topically to the tissue surface.
• Monitor for Thromboembolism: Following surgery, patients should be monitored for signs of abnormal blood clots, such as sudden chest pain or asymmetrical leg swelling.
• Avoid Sponging: Once the clot forms, the area should not be aggressively wiped with sponges, as this can tear the new fibrin clot and restart the bleeding.

“Do’s and Don’ts” List

For the Provider/Surgical Team:

• DO reconstitute the powder using only the provided diluent.
• DO apply the solution directly to the bleeding site or use an approved absorbable gelatin sponge.
• DO blot the tissue with sterile gauze to remove excess blood right before applying the thrombin.
• DON’T inject Recothrom into blood vessels under any circumstances.
• DON’T use this product for massive, spurting arterial bleeding; it is designed for mild to moderate capillary oozing.

For the Patient (Post-Surgery):

• DO inform your surgeon if you have had severe allergic reactions to previous surgeries or specific animal proteins.
• DO tell your care team immediately if you experience sudden shortness of breath, severe headache, or leg pain after your surgery.
• DON’T take blood-thinning medications after surgery without explicit permission from your surgeon or hematologist.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Surgical procedures inherently carry risks of bleeding and clotting. Always consult with your surgeon, anesthesiologist, or a specialist in hematology to discuss all medications and products that will be used during your medical procedure.